Forte Biosciences to be acquired by Argenx for ~$866 million

Forte Biosciences and Argenx announced a definitive merger agreement where Argenx will merge its wholly-owned subsidiary, Aveena Merger Sub, into Forte, valuing Forte at $209 million in cash and 9.8 million Argenx shares. The deal, subject to shareholder approval, is intended to close in the fourth quarter of 2026.